DIFFUSE LARGE B CELL LYMPHOMA

Course overview

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IS THE MOST COMMON LYMPHOMA, ACCOUNTING FOR ABOUT 25% TO 30% OF ALL THE NON-HODGKIN LYMPHOMAS. IT TYPICALLY PRESENTS AS A RAPIDLY GROWING MASS OR ENLARGING LYMPH NODES IN A NODAL OR EXTRANODAL SITE. THOUGH AGGRESSIVE, THEY DO RESPOND WELL TO SIX CYCLES OF RITUXIMAB ALONG WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (R-CHOP). THIS ACTIVITY REVIEWS THE EVALUATION AND TREATMENT OF DLBCL AND HIGHLIGHTS THE ROLE OF THE INTERPROFESSIONAL TEAM IN EVALUATING AND TREATING PATIENTS WITH THIS CONDITION.